Ebola vaccine being used in Congo produces lasting antibody response, study finds
Changing your diet could add up to a decade to life expectancy, study finds
8 February 2022Research reveals why more Black women die from breast cancer
8 February 2022Ebola vaccine being used in Congo produces lasting antibody response, study finds
A new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSVΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.
